US Senate Approves Measures to Curb Chinese Biotech Funding and Investment
The US Senate has approved two bipartisan measures as part of the National Defence Authorisation Act. The Biosecure Act aims to prohibit federal funding for Chinese biotech companies deemed as 'biotechnology companies of concern'. The FIGHT China Act restricts US investment in critical Chinese technological areas including AI models, hypersonic missiles, advanced semiconductors, quantum computers, and military products. The measures also allow for sanctions. Companies potentially affected include BGI Group, MGI Tech Co., Complete Genomics Inc., WuXi AppTec Co., and WuXi Biologics. The bills still need to pass through the House of Representatives and receive presidential approval to become law.

*this image is generated using AI for illustrative purposes only.
The United States Senate has taken significant steps to address national security concerns related to Chinese companies, approving two bipartisan measures as part of the National Defence Authorisation Act. These measures aim to restrict federal funding for certain Chinese biotech firms and limit US investment in key Chinese technological sectors.
Biosecure Act: Targeting Chinese Biotech Companies
The first measure, known as the Biosecure Act, focuses on prohibiting federal funding for Chinese biotech companies deemed as 'biotechnology companies of concern'. This act includes a provision for the administration to grant one-year waivers, allowing for some flexibility in its implementation.
FIGHT China Act: Restricting US Investment
The second measure, the FIGHT China Act, takes a broader approach by restricting US investment in several critical technological areas. These include:
| Restricted Areas for US Investment | |:-----------------------------------|: | Chinese AI models | | Hypersonic missiles | | Advanced semiconductors | | Quantum computers | | Military products |
Additionally, this act authorizes sanctions, further strengthening its potential impact on US-China economic relations.
Companies Under Scrutiny
While the legislation does not explicitly name companies, several Chinese firms have been previously identified for potential scrutiny. These include:
| Companies Previously Identified | |:--------------------------------|: | BGI Group | | MGI Tech Co. | | Complete Genomics Inc. | | WuXi AppTec Co. | | WuXi Biologics |
Legislative Process
It's important to note that these measures are not yet law. For them to take effect:
- Both the House of Representatives and the Senate must agree on identical bills.
- The President must sign the agreed-upon bill to enact it into law.
Implications
These legislative actions reflect growing concerns in the United States about:
- National security implications of Chinese technological advancements
- The need to protect sensitive sectors from potential foreign influence or control
As these measures progress through the legislative process, they could significantly impact US-China relations and the global technology landscape. Stakeholders in affected industries should closely monitor developments and prepare for potential changes in the regulatory environment.